Spine Biopharma Inc. cited an “inconsistent sham control response” among some of the sites in its phase III study testing SB-01 as an intradiscal treatment for patients with chronic low back pain ...
Final Phase 2 data show casdozokitug with atezolizumab/bevacizumab achieves a 17.2% complete response rate in HCC patients. Coherus BioSciences, Inc. announced ...
Adicet Bio Inc. (NASDAQ:ACET) shares fell Tuesday after the biotechnology company priced an $80 million direct offering, even as early safety and efficacy data from its Phase 1 trial of ADI-001 in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback